MDGL icon

Madrigal Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 75%
Negative

Neutral
GlobeNewsWire
8 days ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Positive
Zacks Investment Research
19 days ago
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Positive
The Motley Fool
20 days ago
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Neutral
GlobeNewsWire
27 days ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Positive
The Motley Fool
1 month ago
2 Under-the-Radar Stocks to Buy and Hold
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
2 Under-the-Radar Stocks to Buy and Hold
Neutral
GlobeNewsWire
1 month ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 month ago
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M.
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Negative
Zacks Investment Research
1 month ago
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Neutral
Seeking Alpha
1 month ago
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates